Scalper1 News
The drama continued for big biotech Gilead Sciences Tuesday, as Johnson & Johnson moved into its viral-disease turf on two fronts with an acquisition. Johnson & Johnson (JNJ) disclosed that it’s buying privately held Alios BioPharma for $1.75 billion in cash. In a press release, J&J touted Alios’ drug candidate for respiratory syncytial virus (RSV), a major cause of lung infection that has no current treatment. The drug, AL-8176, is Scalper1 News
Scalper1 News